These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 34100771)
1. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas. Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771 [TBL] [Abstract][Full Text] [Related]
2. Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases. Zhang W; Lv Y; Xue Y; Wu C; Yao K; Zhang C; Jin Q; Huang R; Li J; Sun Y; Su X; Jiang T; Fan X Oncotarget; 2016 Sep; 7(37):59098-59114. PubMed ID: 27385209 [TBL] [Abstract][Full Text] [Related]
3. Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. Sakata K; Kato S; Fox JC; Shigemori M; Morimatsu M J Neuropathol Exp Neurol; 2002 Nov; 61(11):975-83. PubMed ID: 12430714 [TBL] [Abstract][Full Text] [Related]
4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
5. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. Choi C; Kwon J; Lim S; Helfman DM Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827 [TBL] [Abstract][Full Text] [Related]
6. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Iida M; Harari PM; Wheeler DL; Toulany M Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136 [TBL] [Abstract][Full Text] [Related]
7. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival. Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266 [TBL] [Abstract][Full Text] [Related]
8. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115 [TBL] [Abstract][Full Text] [Related]
9. Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression. Tu W; Yang B; Leng X; Pei X; Xu J; Liu M; Dong Q; Tao D; Lu Y; Liu Y; Yang Y Cancer Sci; 2019 May; 110(5):1573-1586. PubMed ID: 30815935 [TBL] [Abstract][Full Text] [Related]
10. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698 [TBL] [Abstract][Full Text] [Related]
11. Antitumor mechanism of kangliu pill on gliomas in mice through PI3K-Akt signaling pathway. Chen F; Cui JJ; Jiang DC; Wang HZ; Zhuang W; Feng YN; Lin XL; Xi SY J Ethnopharmacol; 2023 May; 307():116252. PubMed ID: 36775078 [TBL] [Abstract][Full Text] [Related]
12. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Yadav V; Denning MF Mol Carcinog; 2011 May; 50(5):346-52. PubMed ID: 21480388 [TBL] [Abstract][Full Text] [Related]
14. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. Besset V; Scott RP; Ibáñez CF J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment. Lin A; Gu T; Hu X; Zhang J; Luo P J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003 [TBL] [Abstract][Full Text] [Related]
17. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897 [TBL] [Abstract][Full Text] [Related]
18. Effects of Fibronectin 1 on Cell Proliferation, Senescence and Apoptosis of Human Glioma Cells Through the PI3K/AKT Signaling Pathway. Liao YX; Zhang ZP; Zhao J; Liu JP Cell Physiol Biochem; 2018; 48(3):1382-1396. PubMed ID: 30048971 [TBL] [Abstract][Full Text] [Related]